Table 3. Effectiveness of COVID-19 vaccines in preventing hospitalization and death among adults aged 18 years and older by age group, vaccination series and vaccine.
| Complete Series (95% CI) | Complete Series + booster (95% CI) | ||||
|---|---|---|---|---|---|
| Hospitalization | Death | Hospitalization | Death | ||
| Age group | |||||
| 18 years and older | 82.7% (82.1 – 83.2) | 86.0% (85.5 – 86.5) | 80.2% (78.7–81.6) | 83.1% (81.5–84.5) | |
| 18–44 years | 91.5% (90.4 – 92.4) | 95.1% (93.5 – 96.3) | 89.7% (85.1–92.9) | 89.5% (74.0–95.8) | |
| 45–59 years | 83.2% (81.6 – 84.7) | 90.5% (89.0 – 91.8) | 71.5% (62.4–78.4) | 74.0% (59.5–83.3) | |
| 60–69 years | 87.1% (86.0 – 88.2) | 91.7% (90.7 – 92.6) | 81.3% (77.0–84.8) | 83.8% (78.4–87.9) | |
| 70–79 years | 85.9% (84.9 – 86.8) | 90.0% (89.1 – 90.8) | 84.0% (81.5–86.1) | 86.8% (84.2–89.0) | |
| 80 years and older | 75.2% (74.0 – 76.3) | 78.5% (77.4 – 79.5) | 76.8% (74.3–79.1) | 80.3% (77.9–82.5) | |
| Vaccine: Ad26.COV2-S | One dose | Two doses | |||
| 18 years and older | 85.4% (83.8 – 86.9) | 90.5% (88.8 – 91.9) | 89.0% (78.7–94.3) | 77.6% (55.0–88.9) | |
| 18–44 years | 90.7% (88.9 – 92.2) | 93.1% (89.7 – 95.4) | 95.6% (86.0–98.6) | -- | |
| 45–59 years | 78.0% (73.6 – 81.7) | 86.0% (81.1 – 89.6) | 71.9% (11.0–91.1) | -- | |
| 60–69 years | 80.6% (74.5 – 85.2) | 88.0% (82.3 – 91.8) | -- | -- | |
| 70–79 years | 82.7% (76.4 – 87.4) | 88.2% (82.5 – 92.1) | 87.1% (83.0–98.2) | -- | |
| 80 years and older | 86.4% (80.0 – 90.7) | 86.9% (80.9 – 91.1) | -- | -- | |
| Vaccine: BNT162b2 | Two doses | Three doses | |||
| 18 years and older | 90.5% (89.8 – 91.2) | 93.5% (92.8 – 94.2) | 89.6% (86.0–92.2) | 89.6% (84.5–92.9) | |
| 18–44 years | 91.2% (89.1 – 92.9) | 97.0% (93.7 – 98.6) | 87.0% (71.7–94.0) | -- | |
| 45–59 years | 87.7% (85.8 – 89.3) | 93.8% (92.0 – 95.1) | 82.8% (67.0–91.0) | 82.3% (50.9–93.6) | |
| 60–69 years | 90.7% (89.3 – 91.9) | 93.1% (91.7 – 94.3) | 86.7% (78.1–91.9) | 88.0% (75.3–94.1) | |
| 70–79 years | 92.4% (91.0 – 93.6) | 94.9% (93.7 – 95.9) | 93.9% (88.3–96.9) | 91.6% (83.0–95.8) | |
| 80 years and older | 88.5% (85.4 – 90.9) | 89.1% (86.2 – 91.4) | 88.8% (70.1–95.8) | 90.2% (69.5–96.9) | |
| Vaccine: ChAdOx1 nCoV-19 | Two doses | Three doses | |||
| 18 years and older | 88.0% (86.8 – 89.1) | 92.6% (91.5 – 93.6) | 78.4% (72.6–82.9) | 84.5% (77.9–89.2) | |
| 18–44 years | 97.3% (95.4 – 98.4) | 99.1% (93.4 – 99.9) | -- | -- | |
| 45–59 years | 85.5% (81.0 – 89.0) | 91.4% (86.5 – 94.5) | 87.0% (69.0–98.2) | -- | |
| 60–69 years | 88.1% (86.0 – 89.9) | 94.2% (92.5 – 95.6) | 71.2% (58.6–80.0) | 80.5% (64.8–89.2) | |
| 70–79 years | 90.5% (88.7 – 91.9) | 94.3% (92.9 – 95.4) | 82.4% (74.8–87.6) | 87.1% (78.6–92.2) | |
| 80 years and older | 81.7% (76.9 – 85.5) | 87.9% (84.0 – 90.9) | 85.2% (60.6–94.5) | 86.8% (58.8–95.7) | |
| Vaccine: CoronaVac | Two doses | Three doses | |||
| 18 years and older | 77.4% (76.5 – 78.2) | 81.9% (81.2 – 82.7) | 71.3% (68.3–74.0) | 76.3% (73.3–79.0) | |
| 18–44 years | 87.5% (84.6 – 89.8) | 92.7% (88.0 – 95.6) | 90.4% (69.2–97.0) | -- | |
| 45–59 years | 76.3% (72.8 – 79.4) | 86.8% (83.3 – 89.5) | 62.0% (31.1–79.1) | -- | |
| 60–69 years | 82.6% (80.2 – 84.6) | 88.1% (85.9 – 90.0) | 80.1% (67.6–87.8) | 64.9% (38.5–79.9) | |
| 70–79 years | 81.7% (80.2 – 83.1) | 86.6% (85.3 – 87.7) | 75.5% (70.2–79.8) | 81.2% (75.7–85.5) | |
| 80 years and older | 73.6% (72.2 – 74.8) | 77.0% (75.8 – 78.1) | 68.4% (64.2–72.1) | 74.9% (71.0–78.2) | |
| Vaccine: mRNA-1273 | Two doses | Three doses | |||
| 18 years and older | 93.7% (91.8 – 95.2) | 95.7% (93.5 – 97.2) | -- | -- | |
| 18–44 years | 97.5% (96.1 – 98.3) | 97.9% (94.3 – 99.2) | -- | -- | |
| 45–59 years | 91.6% (86.0 – 94.9) | 93.5% (86.3 – 96.9) | -- | -- | |
| 60–69 years | 94.4% (87.6 – 97.5) | 97.8% (91.0 – 99.4) | -- | -- | |
| 70–79 years | 93.7% (86.0 – 97.2) | 95.5% (88.1 – 98.3) | -- | -- | |
| 80 years and older | 89.7% (77.0 – 95.4) | 92.3% (81.4 – 96.8) | -- | -- | |
| Heterologous Booster | |||||
| Combination: BNT162b2 + BNT162b2 + mRNA-1273 (n 527 225) | |||||
| 18 years and older | · · | · · | 87.5% (83.6–90.4) | 92.2% (87.7–95.1) | |
| 18–44 years | · · | · · | 85.9% (70.7–93.2) | -- | |
| 45–59 years | · · | · · | 78.3% (62.5–87.4) | 79.5% (48.1–91.9) | |
| 60–69 years | · · | · · | 86.6% (78.5–91.6) | 93.5% (84.0–97.3) | |
| 70–79 years | · · | · · | 90.1% (82.1–94.6) | 90.1% (80.0–95.1) | |
| 80 years and older | · · | · · | 91.3% (65.3–97.8) | 95.2% (65.5–99.3) | |
| Combination: BNT162b2 + BNT162b2 + ChAdOx1 nCoV-19 (n 477 208) | |||||
| 18 years and older | · · | · · | 85.4% (80.8–88.8) | 91.2% (85.9–94.5) | |
| 18–44 years | · · | · · | 76.3% (52.4–88.1) | -- | |
| 45–59 years | · · | · · | 57.7% (35.8–72.1) | 84.3% (55.9–94.4) | |
| 60–69 years | · · | · · | 91.8% (84.1–95.8) | 82.9% (67.3–91.0) | |
| 70–79 years | · · | · · | 90.2% (80.3–95.1) | 93.1% (81.5–97.4) | |
| 80 years and older | · · | · · | -- | -- | |
| Combination: CoronaVac + CoronaVac + BNT162b2 (442 836) | |||||
| 18 years and older | · · | · · | 85.9% (82.8–88.5) | 87.1% (83.7–89.8) | |
| 18–44 years | · · | · · | 93.0% (71.5–98.3) | -- | |
| 45–59 years | · · | · · | 73.0% (26.6–90.0) | -- | |
| 60–69 years | · · | · · | 92.1% (68.3–98.0) | 86.0% (43.6–96.5) | |
| 70–79 years | · · | · · | 91.5% (85.8–94.9) | 94.3% (88.0–97.3) | |
| 80 years and older | · · | · · | 83.5% (79.1–86.9) | 84.8% (80.3–88.3) | |
| Combination: CoronaVac + CoronaVac + ChAdOx1 nCoV-19 (280 245) | |||||
| 18 years and older | · · | · · | 82.8% (78.4–86.3) | 83.6% (78.7–87.5) | |
| 18–44 years | · · | · · | 87.5% (60.2–96.1) | -- | |
| 45–59 years | · · | · · | 79.6% (44.5–92.5) | 86.9% (52.0–98.2) | |
| 60–69 years | · · | · · | 80.6% (62.2–90.0) | 89.2% (66.1–96.6) | |
| 70–79 years | · · | · · | 85.6% (77.3–90.9) | 83.3% (72.8–89.7) | |
| 80 years and older | · · | · · | 81.8% (75.0–86.7) | 81.9% (74.7–87.1) | |
| Combination: CoronaVac + CoronaVac + mRNA-1273 (313 044) | |||||
| 18 years and older | · · | · · | 85.5% (82.5–87.9) | 87.8% (84.8–90.1) | |
| 18–44 years | · · | · · | 94.5% (60.2–99.2) | - | |
| 45–59 years | · · | · · | 64.1% (22.6–83.3) | -- | |
| 60–69 years | · · | · · | 75.9% (55.7–86.8) | 78.0% (50.1–90.3) | |
| 70–79 years | · · | · · | 88.6% (83.6–92.1) | 91.1% (85.8–94.4) | |
| 80 years and older | · · | · · | 86.0% (82.2–89.0) | 87.3% (83.5–90.2) | |
.. Not applicable -- Not estimable